Katie Woodhall, Safety Director at The Beaver Companies, joins 3rd episode of CheckProof’s Podcast

Following on from the success of previous episodes of Breaking Ground – A CheckProof Podcast, the latest episode, 'Safety Leadership in Practice', features Katie Woodhall, Director of Safety at The Beaver Companies, including Beaver Excavating, Beaver Constructors, Inc., Stone Products, Inc., & Tractor Parts. https://mma.prnewswire.com/media/2649697/CheckProof_Logo.jpg From a fourth-generation mining family with extensive experience leading safety […]

Castelion Secures Multiple Awards to Integrate Blackbeard Hypersonic Strike Weapon on U.S. Army and U.S. Navy Platforms

Castelion, a U.S. defense technology company developing affordable, long-range strike weapons, announced today that it has been awarded integration contracts for its Blackbeard weapon system with operational U.S. Army and U.S. Navy platforms. https://mma.prnewswire.com/media/2804208/Castelion_Logo.jpg Under these agreements, Castelion will work with both services to integrate the hypersonic Blackbeard weapon system onto operational platforms and demonstrate

MicroCloud Hologram Inc. Releases Hybrid Quantum-Classical Convolutional Neural Network, Achieving New Breakthrough in MNIST Multi-Class Classification

(NASDAQ:HOLO), SHENZHEN, China, Oct. 24, 2025 (GLOBE NEWSWIRE) — MicroCloud Hologram Inc. (NASDAQ: HOLO), (“HOLO” or the “Company”), a technology service provider, proposed a Quantum Convolutional Neural Network (QCNN) based on hybrid quantum-classical learning and successfully applied it to the multi-class classification problem on the MNIST dataset, achieving accuracy comparable to classical Convolutional Neural Networks

Scout Clean Energy and Partners Hold Blade Signing Ceremony for Nimbus Wind Farm

(NYSE:BAM),(TSX:BAM), GREEN FOREST, Ark., Oct. 24, 2025 (GLOBE NEWSWIRE) — Scout Clean Energy (“Scout”), a leading North American renewable energy developer-owner-operator, held a blade signing event yesterday at the Nimbus Wind Farm (“Nimbus”) in Green Forest, Arkansas, joining project stakeholders to celebrate the project's successful progress as construction continues. Joining Scout staff at the event

No KYC. 100x Leverage. $100 Welcome Bonus. Crypto Futures Trading Made Easy on BexBack.

SINGAPORE, Oct. 24, 2025 (GLOBE NEWSWIRE) — With Bitcoin's price fluctuating below $110,000, many analysts predict a prolonged period of high volatility in the crypto market. Holding spot positions may struggle to generate short-term profits in such conditions. As a result, 100x leverage futures trading has become the preferred tool for seasoned investors looking to

Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety

(NasdaqGM:MRUS), – 100% response rate in 1L left-sided mCRC (n=8, confirmed and unconfirmed) – 62% response rate in 2L left- and right-sided mCRC (n=13, confirmed and unconfirmed) UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length

Remix Therapeutics Announces Positive Preliminary Data from Phase 1 Study of REM-422 in Patients with Adenoid Cystic Carcinoma at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Preliminary Results Yield 43% Overall Response Rates (via RECIST) in the Efficacy Population Data Demonstrate REM-422, the First-in-Class Small Molecule MYB mRNA Degrader, Reduces Expression of the MYB Oncogene WATERTOWN, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) — Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the

Halda Therapeutics Announces First-in-Human Results for HLD-0915, an Oral RIPTAC(TM) Therapeutic Demonstrating Encouraging Safety and Anti-Tumor Activity in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Anti-tumor activity was observed in heavily pretreated mCRPC patients across all dose cohorts; in 22 patients who completed at least 2 cycles of therapy, 59% achieved PSA50 response and 32% achieved PSA90 response All 5 patients (5/5) with measurable disease according to RECIST criteria achieved a partial response (PR), all by the first response assessment

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcturus Therapeutics Holdings Inc. – ARCT

(NasdaqGM:ARCT), NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Arcturus Therapeutics Holdings Inc. (“Arcturus” or the “Company”) (NASDAQ: ARCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Arcturus and certain of its officers and/or directors

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mr. Cooper Group Inc. – COOP

(NASDAQ:COOP), NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Mr. Cooper Group Inc. (“Mr. Cooper” or the “Company”) (NASDAQ: COOP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Mr. Cooper and certain of its officers

Scroll to Top